clinical trial · NCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Exelixis·phase3·recruiting·n = 440
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)ZanzalintinibEverolimus
brief summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
started
Jul 21, 2025
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
Apr 17, 2026
official title
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol